Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + clopidogrel is a combination antiplatelet regimen utilized as the standard medical therapy arm in clinical trials for stroke prevention, specifically in patients with symptomatic intracranial arterial stenosis. This regimen typically involves dual antiplatelet therapy (DAPT) with aspirin, an irreversible inhibitor of prostaglandin G/H synthase 1 (COX-1), and clopidogrel, a thienopyridine-class P2Y12 receptor antagonist. By inhibiting both the thromboxane A2 and adenosine diphosphate (ADP) pathways of platelet activation, the combination provides synergistic antithrombotic effects. In the context of the study by Can Tho Stroke International Services Hospital, the treatment protocol consists of 90 days of DAPT (aspirin 100 mg and clopidogrel 75 mg) followed by clopidogrel monotherapy to prevent recurrent ischemic events in the territory of the symptomatic intracranial artery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + clopidogrel.